| Nov 19 |
Tevogen Bio Holdings reports Q3 results
|
| Nov 19 |
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
|
| Nov 14 |
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
|
| Nov 14 |
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
|
| Nov 8 |
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
|
| Nov 5 |
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
|
| Nov 5 |
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
|
| Nov 4 |
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
|
| Oct 31 |
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
|
| Oct 29 |
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
|
